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Because dopamine D1 receptors (DRD1) influence renal
sodium transport and vascular hemodynamics, we examined
whether genetic polymorphisms play a role in renal function.
We conducted polymorphism discovery across the DRD1
open reading frame and its 50-UTR and then performed
association studies with estimated glomerular filtration rate
(eGFR), plasma creatinine (pCr), and fractional excretion of
uric acid (FeUA). We used a twin/family group of 428 subjects
from 195 families and a replication cohort of 677 patients
from the Kaiser health-care organization sampled from the
lower percentiles of diastolic blood pressures. Although the
coding region lacked common non-synonymous variants, we
identified two polymorphisms in the DRD1 50-UTR (G-94A,
A-48G) that occurred with frequencies of 15 and 30%,
respectively. In the twin/family study, renal traits were highly
heritable, such that DRD1 G-94A significantly associated with
eGFR, pCr, and FeUA. Homozygotes for the G-94A minor
allele (A/A) exhibited lower eGFR, higher pCr, and lower FeUA.
No effects were noted for DRD1 A-48G. Patients in the Kaiser
group had similar effects of G-94A on eGFR and pCr. Kidney
cells transfected with the -94A variant but not the wild type
vectors had increased receptor density. Because the -94A allele
is common and may reduce glomerular capillary hydrostatic
pressure, G-94A profiling may aid in predicting survival of
renal function in patients with progressive renal disease.
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Dopamine and its receptors regulate sodium transport
and hemodynamics through alterations in vascular smooth
muscle contractility, including interactions with other
neurohormonal factors such as the renin–angiotensin–
aldosterone and sympathetic nervous systems; accordingly,
the dopaminergic system has been extensively studied
in hypertension.1 Five dopamine receptor subtypes, all
G-protein-coupled receptors, have been identified (D1, D2,
D3, D4, and D5), and classified into two functional
subgroups: D1-like receptors, which stimulate adenylyl
cyclase, and D2-like receptors, which inhibit adenylyl cyclase.
The D1 dopamine receptor (DRD1), a member of the D1-like
receptor subfamily, is expressed in the kidney, largely in
the proximal tubule as well as in the vasculature (both
afferent and efferent arterioles), and increases urine flow rate
and sodium excretion when activated systemically or
intrarenally.2
DRD1 has been associated with hypertension in animal
studies, including in D1a-knockout mice,3 and in human
studies.3–5 Genetic polymorphisms of DRD1 have been
implicated in human essential hypertension6,7 and renal
tubular sodium disposition.7 As dopamine is produced
intrarenally and may act locally in the kidney, multiple
effects of DRD1 receptors may contribute to the patho
genesis of hypertension through alterations in renal
function.8
Here we sought to identify DRD1 genetic polymorphisms
through systematic polymorphism discovery, to evaluate
such variants’ ability to influence glomerular and tubular
function, and to assess the effects of trait-associated
polymorphism on receptor expression and function in
transfected cells.
RESULTS
DRD1 polymorphism discovery: 50-UTR variants
We undertook polymorphism discovery at DRD1 by PCR
amplifying a 1572-bp fragment (Figure 1) spanning the open
reading frame (ORF) and 187 bp of 50-UTR (untranslated
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region) and 45 bp of 30-UTR. When the amplicon was
sequenced in 27 white individuals (54 chromosomes), no
variants that altered encoded amino acids were noted in the
ORF. However, we found two common variants in the
50-UTR (numbering upstream of the ATG initiation codon):
G-94A and A-48G.
We then evaluated these two variants in a larger sample
(see below twin/family study) of 428 white subjects to
determine allele and haplotype frequencies. Taking one
subject per family (n¼ 195), the minor allele frequency for
G-94A was 15% and for A-48G was 30%. The naturally
occurring 50-UTR haplotypes (across G-94A-A-48G) were
GA (at 60% of chromosomes), GG (at 26%), AA (at 13%),
and AG (at 0.5%). In these white subjects, the two alleles were
in strong (though not complete) linkage disequilibrium
(D0 ¼ 0.81, r2¼ 0.05, from 195 subjects, taking one per
family).
Twin/family study: association of DRD1 50-UTR polymorphism
G-94A with renal function
Table 1 describes the twin/family study. The 428 subjects, self-
identified as white, from 195 families, were predominantly
female (74%), with a mean age of 40.3 years. Overall, 78%
were twins. Mean systolic blood pressure (SBP) was in the
pre-hypertensive range. Based on a physician’s diagnosis or
on the use of BP medications, only 8.9% reported being
hypertensive, but on the classification of BP status based on
our measurements, 24.3% were in the hypertensive range
(SBPX140 or diastolic blood pressure (DBP)X90), whereas
49.8% were in the pre-hypertensive range (either
120pSBPo140 or 80pDBPo90). Plasma creatinine (pCr)
and estimated glomerular filtration rate (eGFR) were within
normal ranges. Twin (monozygotic versus dizygotic) correla-
tions (evaluated using SOLAR, Sequential Oligogenic Linkage
Routines) established that the traits under consideration
showed substantial heritability (h2 values of B41 to 78%),
with especially high h2 for eGFR at 77.6±3.4%
(P¼ 7.67E26, Table 1).
Table 2 indicates that multiple markers of renal function
were significantly associated with the DRD1 G-94A poly-
morphism: eGFR, pCr, urine uric acid: creatinine ratio, and
fractional excretion of uric acid (FeUA), all of which
maintained significance with permutation testing, which
also adjusted for the multiple genetic models tested.
Figure 2a illustrates an apparently recessive effect of the
DRD1 G-94A A allele on eGFR. Subjects with wild-type
(G/G) or heterozygous (G/A) genotypes had higher eGFR
than those homozygous for the minor allele (A/A, P¼ 0.013).
pCr showed a similar effect of the genotypes: subjects with
minor allele homozygosity (A/A) had higher pCr levels
(0.88±0.19 mg/dl) than did those carrying the G allele
(G/A heterozygotes 0.81±0.20 mg/dl and wild-type G/G
homozygotes 0.84±0.013 mg/dl, P¼ 0.041, Figure 2b), with
sex and age as covariates.
Urinary uric acid excretion (P¼ 0.020) and FeUA
(P¼ 0.039) were also associated with the G-94A polymor-
phism, but showed an apparent additive effect (A/AoG/A
oG/A) on uric acid transport and excretion (Figure 2c).
Table 2 also shows the results of the recessive model
with adjustment for population stratification. pCr levels,
which showed marginal significance before adjustment, was
no longer statistically significant, suggesting population
admixture in these subjects who self-identified as
European-Americans. Significance was maintained for eGFR,
FeUA, and urinary uric acid excretion.
The DRD1 A-48G polymorphism did not associate with
BP or markers of renal function, perhaps consistent with only
partial linkage disequilibrium (D0 ¼ 0.81, r2¼ 0.05) between
the A-48G and G-94A loci. Results after permutation testing
were unchanged.
Human/
mouse
homology
mRNA
BC074978
Human DRD1 coding exon (1659 bp)
Human DRD1 (dopamine D1 receptor):
Coding region and interspecies sequence conservation
→→
G-94A
PCR amplicon (1572 bp) for re-sequencing and expression
Open reading frame (1338 bp)
A-48G
Figure 1 |Human DRD1: coding region and interspecies sequence conservation. The human dopamine D1 receptor (DRD1) coding exon
is shown with indication of the PCR amplicon and open reading frame sequenced in this study. Noted are the 50-UTR polymorphisms,
G-94A and A-48G, confirmed through re-sequencing, and evaluated in association with cardiorenal traits in this study. Plot created at
http://pipeline.lbl.gov/cgi-bin/vistatrack.
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Replication study: the Kaiser normal blood pressure study
Table 3 describes the Kaiser study used to replicate the
findings from the twin/family study, and shows the results of
G-94A polymorphism association studies in the Kaiser
subjects. The 677 subjects consisted of 57% females, all
self-identified as white and without a history of hypertension.
Their mean age was 56.8 years; mean SBP, DBP, pCr, and
eGFR were within the normal ranges. These subjects had
substantially higher mean ages and (consistent with the effect
of age) lower GFR values than those in the twin/family study
(Table 1, Figure 2a).
As we found in the twin/family study, eGFR was predicted
by the DRD1 G-94A polymorphism, with lower eGFR in
minor allele homozygotes (A/A, 66.1±0.9 ml/min per
1.73 m2, compared with G/A (79.2±1.4) and G/G
(77.5±0.8, P¼ 0.020; Table 3 and Figure 2a). Table 3 and
Table 1 | Demographic and genotypic data for the twin/family study
Twin/family study (n¼ 428) Mean Standard error
Heritability (h2) %
±s.e.m. (P-value)
Trait
Age (years) 40.3 0.80 N/A
SBP (mmHg) 130.7 0.76 46.3±6.4 (P¼ 1.68E09)
DBP (mmHg) 70.9 0.47 52.7±5.9 (P¼ 2.77E12)
eGFR (by MDRD ml/min per 1.73m2) 96.4 1.3 77.6±3.4 (P¼ 7.67E26)
Plasma creatinine (mg/dl) 0.80 0.0075 76.3±3.7 (P¼ 3.04E23)
Plasma uric acid (mg/dl) 4.2 0.056 0.34±0.074 (P¼ 1.79E5)
Urine study
Uric acid/creatinine (g/g) 0.35 0.013 44.8±6.8 (P¼ 1.49E08)
FeUA 0.072 0.0033 41.5±7.6 (P¼ 1.6E07)
Participants: 195 families Twins: 78.7% Parents/siblings: 21.3%
Sex Female: 78% Male: 22%
Ethnicity by self-report White/European-American: 100%
Blood pressure status by self-report Normotensive: 91.1% Hypertensive: 8.9%
Blood pressure category by measurements Normotensive: 25.9% Pre-hypertensive: 49.8% Hypertensive: 24.3%
Family history of hypertension Yes: 42.8% No: 48.6% Unknown: 8.6%
DRD1 polymorphisms: verification of SNP genotyping results by re-sequencing
DRD1 G-94A, rs 5326 G/G: 320 G/A: 57 A/A: 26
HWE w2¼ 35, Po0.001 Re-sequencing of 48 individuals: 100% concordance
DRD1 A-48G, rs4532 A/A: 193 A/G 125 G/G: 63
HWE w2¼ 6.9, P¼ 0.009 Re-sequencing of 48 individuals: 97.9% concordance
DBP, diastolic blood pressure; eGFR, glomerular filtration rate; FeUA, fractional excretion of uric acid; HWE, Hardy–Weinberg equilibrium; MDRD, Modification of Diet in Renal
Disease; SBP, systolic blood pressure; SNP, single-nucleotide polymorphism.
Means and standard errors are reported for continuous traits. Trait heritability values are from a subset of this study (n¼ 374) and have been partially reported previously.9 As
the polymorphisms were out of HWE with results reported using one founder per family (HWE), re-sequencing was performed to confirm genotyping quality. Polymorphism
genotyping was carried out on the Sequenom MALDI-TOF platform. Re-sequencing was carried out on an ABI-3100 capillary device. rs, RefSNP (http://www.ncbi.nlm.nih.gov).
Table 2 | Results of association study of DRD1 G-94A polymorphism with traits associated with hypertension and renal function
in the twin/family study
DRD1 G-94A diploid genotype Significance (P-value)
Twin/family study G/G n=320 G/A n=57 A/A n=26
Additive
model
Recessive
model
Permutation
test
Adjusted for
population
stratification
Trait
SBP (mmHg) 133.0±1.0 132.7±1.7 136.4±3.8 40.06 40.06 — —
DBP (mmHg) 72.0±2.4 71.3±1.2 75.1±2.4 40.06 40.06 — —
eGFR (by MDRD, ml/min per 1.73m2) 100.3±2.2 104.3±3.4 93.2±2.7 0.024* 0.013* 0.014* 0.019*
Plasma creatinine (Cr, mg/dl) 0.84±0.013 0.81±0.020 0.88±0.019 0.056 0.041 0.042 0.090
Plasma uric acid (mg/dl) 4.44±0.083 4.64±0.19 4.72±0.41 40.06 40.06 — —
Urine study
Uric acid/Cr (g/g) 0.35±0.018 0.30±0.027 0.20±0.030 0.020a 0.0088a 0.006a 0.0083a
FeUA 0.069±0.0043 0.056±0.0062 0.041±0.0071 0.039a 0.029a 0.026a 0.025a
No associations were noted for the DRD1A-48G polymorphism. For abbreviations, see Table 1. Additive model: three groups: G/G, G/A, and A/A. Recessive model: G/G and G/A
groups combined. Permutation testing was carried out on significant results, without any significant changes; P-values from adjustment for population stratification and
permutation testing are reported for the recessive models. Age and sex were covariates in all analyses except where noted by * (for eGFR).
aSquare root transformation carried out for normalization with presentation of geometric means. Bold P-values denote Po0.05.
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Figure 2b illustrate the similar association of pCr with
genotype; those homozygous for the minor allele (A/A) had
the highest pCr levels (P¼ 0.007). The results of permutation
testing and adjustment for population stratification in the
recessive models, indicating no changes in statistical
significance, are shown in Table 3.
When analyzing the twin/family study with the Kaiser
study in a combined analysis, significance was maintained
for the DRD1 G-94A polymorphism and pCr (P¼ 0.011,
covariates: sex, age, study group) and for eGFR (P¼ 0.0031,
covariate: study group).
Heterologous expression and binding of the DRD1 receptor
in transfected cells: 50-UTR variant -94A increases receptor
number
Three common haplotypes occurred across the 50-UTR,
capturing 499% of human chromosomes (from G-94A-
A-48G), including G-A (60% of chromosomes), G-G
(26%), and A-A (13%). We thus studied these three combi-
nations in transfected cells to probe the mechanism whereby
the G-94A variant influenced renal traits. Three plasmids
were generated, under the control of the CMV promoter,
which expressed the DRD1 coding region and common
upstream 50-UTR sequence: wild type (WT; G-94-A-48
alleles) and each 50-UTR variant, -94A (with A-48) and -48G
(with G-94).
The three constructs were transiently transfected into
COS-7 kidney cells followed by radioligand binding assays.
In order to quantitate receptor number in the transfected
cells, we incubated them with a fixed concentration of
[3H]SCH23390, a dopamine receptor antagonist, and with
increasing concentrations of SCH23390 (7-chloro-3-methyl-
1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol). Figure 3a
indicates that cells transfected with the -48G sequence had
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Figure 2 | Effects of the DRD1 G-94A polymorphism on human renal traits. (a) DRD1 G-94A effects on estimated glomerular filtration
rate (eGFR) by MDRD algorithm in the twin/family and Kaiser normal blood pressure studies. The results of the twin/family study are on the
x-axis, and those of the Kaiser normal blood pressure study are on the y-axis. Subjects homozygous for the minor allele (A/A) had lower
eGFR than those who were homozygous for the major allele (G/G) or were heterozygous (G/A), indicating an A-allele recessive effect. Thus,
P-values are reported for the recessive model (G/G and G/A versus A/A) in the twin/family study (P¼ 0.013) and the Kaiser study (P¼ 0.020).
MDRD, Modification of Diet in Renal Disease. (b) DRD1 G-94A on plasma (pCr) or serum (sCr) creatinine concentration in the twin/family and
Kaiser normal blood pressure studies. The results of the twin/family study are on the x-axis and the Kaiser study on the y-axis. Subjects who
are minor allele homozygous (A/A) at the allele had higher pCr than those who were major allele homozygous (G/G) or heterozygous (G/A),
again illustrating an A-allele recessive effect. P-values are thus reported for the recessive model (G/G and G/A versus A/A) in the twin/family
study (P¼ 0.041) and in the Kaiser study (P¼ 0.007). Sex and age are included as covariates in the model. (c) Effects of DRD1 G-94A on
urinary uric acid excretion (urine uric acid:creatinine ratio and fractional excretion of uric acid (FeUA)) in the twin/family study. FeUA is on
the left y-axis, whereas urine uric acid:creatinine ratio is on the right y-axis. An additive effect is noted for both urinary uric acid excretion
measures, with the minor allele homozygotes (A/A) showing the least excretion, major allele homozygotes (G/G) with the most excretion,
and heterozygotes (G/A) with an intermediate effect. For the additive models: urine uric acid:creatinine ratio with P¼ 0.020 and FeUA with
P¼ 0.039. P-values are reported from square-root transformed data for normalization. Sex and age were covariates in these analyses.
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similar binding properties (number of binding sites,
Bmax, and affinity for radioligand, Kd) to those transfected
with the WT expression plasmid. In contrast, cells trans-
fected with the -94A sequence had similar Kd values
(B0.36±0.05 nM) but a 2.5-fold higher Bmax than those
transfected with either WT or -48G. Studies conducted with
replicate transfections are shown in Figure 3b: cells
transfected with the -94A sequence showed significantly
higher expression relative to cells that expressed the WT
sequence (7093±318 vs 2580±420 fmol per mg protein,
n¼ 3, Po0.01), whereas cells transfected with the -48G
sequence showed a similar number of receptors as did WT
(2269±370 fmol per mg protein). To control for transfection
efficiency, we also co-transfected a luciferase reporter plasmid
(pGL3-Promoter). Even with such normalization, cells
transfected with the -94A sequence showed higher receptor
expression than did those transfected with the WT sequence
(1.51 vs 0.89 104 fmol/RLU (relative light units), n¼ 3,
Po0.05; data not shown). DRD1 receptors in cells trans-
fected with the three plasmids had similar Kd values for
[3H]SCH23390 (WT, 0.42±0.19 nM; -48G, 0.38±0.18 nM;
and -94A, 0.36±0.05 nM).
mRNA structure: bioinformatics of DRD1 G-94A
G-94A is located in an mRNA region highly conserved across
primate species (Figure 4), with the G allele ancestral.
Table 3 | Demographic data for the Kaiser normal blood pressure study and associations with the DRD1 G-94A
Trait statistic
DRD1 G-94A diploid genotype
(HWE v2¼ 0.13, P¼ 0.71) Significance (P-value)
Kaiser normal blood
pressure study (n¼ 677) Mean
Standard
error
G/G
(n¼ 466)
G/A
(n¼ 165)
A/A
(n¼ 13)
Additive
model
Recessive
model
Permutation
test
Adjusted for
population
stratification
Trait
Age (years) 56.8 0.58 N/A N/A — —
SBP (mmHg) 108 0.57 108.5±0.6 108.0±1.1 109.0±3.8 40.06 40.06 — —
DBP (mmHg) 56 0.16 56.9±0.2 56.3±0.3 56.4±1.1 40.06 40.06 —
eGFR (by MDRD,
ml/min per 1.73m2)
77.3 0.70 77.5±0.82 79.2±1.4 66.1±5.4 0.044* 0.020* 0.027* 0.034*
Serum creatinine
(mg/dl)
0.95 0.0079 0.97±0.0083 0.95±0.014 1.1±0.054 0.012 0.007 0.010 0.020
Sex Male: 43% Female: 57%
Ethnicity by self-report 100% White/European-American
DBP, diastolic blood pressure; eGFR, glomerular filtration rate; HWE, Hardy–Weinberg equilibrium; MDRD, Modification of Diet in Renal Disease; SBP, systolic blood pressure.
Means with standard error are reported. Permutation testing was then carried out on significant results, without any significant changes. P-values for adjustment
for population stratification and permutation testing are reported for the recessive models. Sex and age adjusted for all analyses except where indicated * (for eGFR).
Additive model: three groups: G/G, G/A, and A/A; recessive model: G/G and G/A combined. Bold P-values denote Po0.05.
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A search of the local 50-UTR region did not show mRNA
motifs disrupted by G-94A, in particular microRNA
recognition sites, nor did G-94A substantially alter predicted
local RNA stem/loop folding patterns or free energies of
folding (equilibria).
DISCUSSION
Overview
This study reports an association between the DRD1 50-UTR
polymorphism G-94A and eGFR in predominantly normo-
tensive or pre-hypertensive individuals, with replication in an
independent population sample. We found that subjects with
minor allele homozygosity (A/A) at G-94A have decreased
eGFR (Figure 2a) and increased pCr (Figure 2b), suggesting a
recessive action of the A allele on glomerular traits. We
previously reported that DRD1 G-94A also correlates with
albuminuria in this twin/family study.9 Thus, coordinate
actions of the A/A diploid genotype to lower both GFR and
albuminuria suggest diminished glomerular capillary hydro-
static pressure as a potential mechanism. We also found
effects of the genetic variant on renal uric acid transport traits
(Table 2, Figure 2c), suggesting that D1 receptors may
influence other aspects of renal function, as has been
previously suggested.10,11 In addition, we carried out assays
with plasmid constructs of WT and variant DRD1 genes
transfected into heterologous cells and found that the -94A
variant, but not the -48G variant, had increased maximal
binding capacity. To our knowledge, this is the first report
of correlation between DRD1 polymorphisms and renal
function in human subjects and also the first evidence that
the -94A variant alters the number of DRD1 receptors.
DRD1 and renal function
As dopamine and its receptors have a broad spectrum of
actions, including roles in sodium transport, renal hemo-
dynamics, and interactions with other vasoactive substances,
several hypotheses can be posed as to how an increased
DRD1 receptor may affect renal function, although the
literature is inconclusive regarding the comprehensive effects
of dopamine in the kidney, including the roles of both DRD1
and DRD2 receptors. One study in experimental animals
suggested that DRD2 receptors, which typically inhibit
adenylyl cyclase activity, influence glomerular filtration as
opposed to DRD1 receptors, which stimulate adenylyl cyclase
activity.12
Dopamine receptors are present on afferent and efferent
glomerular arterioles,13,14 and thus receptor number may
affect the hemodynamics required for filtration. Increased
dilation of the efferent arteriole would be expected to
decrease glomerular capillary hydrostatic pressure and, hence
GFR, although rat studies have shown that GFR is
maintained despite the vasodilation.15 This is likely attribu-
table to equivalent declines in both pre- and postglomerular
resistance.15 Animal studies have yielded conflicting results
regarding whether the actions of DRD1 receptors on
proximal Naþ reabsorption may trigger reciprocal changes
in GFR through tubuloglomerular feedback.15–18
Although DRD1 activation in smooth muscle myocytes is
generally believed to result in vasodilation, studies in some
animals show interactions between DRD1 and the angioten-
sin type I19 and type II20 receptors, which affect natriuresis in
the proximal tubule and also vasoconstriction. The equiva-
lent receptor (DRD1a) in rats may also trigger secretion of
renin from juxtaglomerular cells,21 particularly when COX2
expression is suppressed.22 Human studies with the DRD1
agonist, fenoldopam, have also suggested increases in
renin–angiotensin activity.23,24 Such an altered milieu of
vasomotor tone modulators may contribute to decreased
eGFR.25 Filtration may be affected by the presence of DRD1
receptors, as documented on podocytes26 and mesangial
cells.27 In addition, mesangial cells may produce catechola-
mines in vitro,28,29 though further studies are needed in this
area.
Using selective DRD1 agonists such as fenoldopam,
human and animal studies have not shown consistent or
substantial changes in GFR after DRD1 receptor activa-
tion.5,23,30 In seven humans with normal BP, an increase in
GFR was noted,23 but a similar study in six hypertensive
subjects did not yield a significant difference in GFR.24
Animal studies have shown that during diabetes- or amino
acid-induced elevation of GFR, fenoldopam may inhibit or
reduce such hyperfiltration.31,32 Our study subjects, particu-
larly in the twin/family study with mean SBP in the pre-
hypertensive range, might exhibit glomerular hyperfiltration,
which could then be attenuated with DRD1 stimulation.
Our heterologous receptor expression results suggest that
increased DRD1 receptor density produced by the -94A
variant may contribute to changes in GFR. Heterozygous D1a
receptor knockout mice exhibited intermediate receptor
density between the WT and knockout,3 suggesting that the
WT (þ /þ ) genotype may be dominant in the mouse, a
finding consistent with the dominant (G) and recessive (A)
actions of G-94A on eGFR and pCr (Figure 2a and b) that we
observed.
Previous studies of DRD1 50-UTR polymorphisms
and their association with hypertension, particularly with
A-48G, have yielded mixed results in various popula-
tions.6,7,33,34 Our study of white subjects, similar to that by
Human G allele (major)  TGCAAAGTGCTGCCTGGTGGGGAGGACTCCT
Human A allele (minor)  TGCAAAGTGCTGCCTAGTGGGGAGGACTCCT
Chimp TGCAAAGTGCTGCCTGGTGGGGAGGACTCCT
Orangutan TGCAAAGGGCTGCCTGGTGGGGAGGACTCCT
Macaque TGCAAGGGGCTGCCTGGTGGGGAGGACTCCT
Conserved ***** * ******* ***************
↑
G-94A
Primate interspecies sequence conservation
in the region of DRD1 5′-UTR variant G-94A
Figure 4 |Primate interspecies sequence conservation in the
region of DRD1 G-94A. Results from Clustal-W alignment
indicate the highly conserved region in the 50-UTR of DRD1
surrounding position -94 across primate species. The ancestral
(non-human primate) allele is G.
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others,33 did not show correlations of the A-48G or G-94A
polymorphisms with BP. The FLEMENGHO group evaluated
the G-94A single-nucleotide polymorphism (SNP) on both
BP and renal traits, although their findings included
haplotype analyses that we did not perform.7 They reported
a decrease in SBP and DBP in subjects with a DRD1
haplotype (-48A, -94G, and -800C). As in our twin/family
and Kaiser normal BP studies, the individual SNPs were not
significantly associated with BP. Given that the C-800T SNP
was not scored in our study, we are unable to evaluate this
haplotype in our cohorts. GFR was not determined in the
FLEMENGHO study, and thus it is uncertain how the BP in
subjects with the DRD1 AGC haplotype may influence renal
function. This group also reported that carriers of the
recessive allele -94A had an increased fractional distal
reabsorption of sodium and decreased fractional excretion
of sodium (FeNa).7 As FeNa and FeUA appear to be
positively associated,35,36 our results of increased FeUA in
the WT (G/G) homozygotes at DRD1 G-94A are consistent
with the FLEMENGHO study, in which FeNa was greater in
WT (G/G).
Precise causal relationships between uric acid and renal
disease remain unresolved, although associations have been
shown.37 Uric acid may have a function in the regulation of
intrarenal vessel function, including interactions with
dopamine10,38 or the renin–angiotensin system.39 Although
genetic influences on the excretion of uric acid have been
established,40 our findings indicate that decreased uric acid
excretion in minor allele homozygotes of G-94A (A/A) may
be linked to a decrease in GFR noted in the same subjects.
Decreased GFR may be mechanistically tied to the decline in
microalbumin excretion in G-94A in minor allele homo-
zygotes (A/A), which has been noted for a subset of this twin/
family study.9 Both changes can be consequences of
diminished glomerular capillary hydrostatic pressure, a
therapeutic goal in patients with glomerular disease.41 Thus,
minor allele homozygosity (A/A) may modify the temporal
course of progressive renal disease. Studies that address this
possibility would be of interest, as positive results would
suggest that profiling patients with chronically declining
renal function by G-94A genotyping might yield a useful
predictor of renal survival. Further studies are necessary to
define the role of DRD1 in renal uric acid transport.
mRNA structure: interspecies conservation
The conservation of the ancestral G allele of DRD1 G-94A
across non-human primates (Figure 4) suggests a region
of functional significance, but the basis of such action(s)
is/are uncertain. Further investigation is necessary to
determine how G-94A variation results in increased receptor
density. Possible mechanisms include alteration of a tran-
scriptional control motif (e.g., an enhancer element),
disruption of the interaction of the 50-UTR with as-yet-
undefined trans-acting factors influencing mRNA stability
or translatability, or perhaps effects on other proposed
regulators of translation.42,43
Advantages and limitations of these studies
Twins. Twin pair studies allowed us to quantify the
heritability (h2) of each cardiorenal trait under consideration,
several of which studied here displayed substantial and
significant h2 (at h2 B41 to 78% of trait variance, Table 1),
thereby indicating the likelihood of genetic effects on such
traits, and setting the stage for tests of particular polymorph-
isms, such as those at DRD1.
Genomics. We systematically scanned the DRD1 coding
exon for common polymorphism (Figure 1) and focused on
the 50-UTR. We found trait associations for a variant in the
DRD1 50-UTR and excluded common non-synonymous
variation in the coding region, but we did not systematically
examine variants in other gene regions, such as the promoter
or the 30-UTR, leaving open the possibility of other
functional variants in control of renal traits.
The frequencies of both DRD1 50-UTR polymorphisms
studied deviated from Hardy–Weinberg equilibrium (HWE)
in the twin/family study (Table 1) but not in the Kaiser
normal BP study. Although 497% concordance with re-
sequencing across the loci renders genotyping error unlikely,
other factors known to perturb HWE might be operative,
including evolutionary forces such as migration or increased
mutation rates. This HWE deviation may also be a sampling
effect of a small population in San Diego, though it was not
noted in the Kaiser group. The polymorphism that yielded
the significant results, G-94A, has been evaluated in previous
association studies,7,33 one of which also found deviation
from HWE in hypertensives.33 The pre-hypertension status
within the twin/family study (almost 50% of the sample) may
also contribute to the deviation from HWE, which was not
seen in the normotensive subjects in the Kaiser cohort.
Even among subjects who self-report as European-
Americans, admixture may confound associations, as ances-
tral groups may harbor genetic variation that is not
associated with changes in gene expression. Thus, we assessed
genetic heterogeneity based on additional genotyping data
available from biallelic markers distributed across the
autosomes, and calculating an identity-by-state (IBS) dis-
tance matrix. The first three multidimensional scaling
components were extracted and used as covariates for a
population structure. As noted in Tables 2 and 3, this
adjustment had minimal influence on statistical significance,
with the exception of pCr in the twin/family study; such
sensitivity of the pCr trait to differential admixture may
reinforce that eGFR (by Modification of Diet in Renal
Disease (MDRD) equation) is a more effective estimator of
glomerular filtration than pCr alone.
Multiple comparisons and replication. With recent in-
creases in genome-wide association studies, concern has
arisen that multiple comparisons may result in false-positive
results. Here, we were able to replicate our findings by
studying two distinct populations: a younger twin/family
cohort with mean age of 40.3±0.8 years and eGFR of
96.4±1.3 ml/min per 1.73 m2 and a Kaiser cohort with a
mean age of 56.8±0.6 years and eGFR of 77.3±0.7 ml/min
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per 1.73 m2. In addition, in this candidate gene study, we
used SNPSpD, proposed by Nyholt,44 to determine that the
two SNPs evaluated (G-94A and A-48G) were in sufficiently
strong linkage disequilibrium that effectively only B1 SNP
was tested, eliminating the need to choose a more stringent
P-value for statistical significance. Results of the cardiorenal
trait associations were also maintained after permutation
testing, which minimizes type I errors due to multiple
comparisons.45
Multiple comparisons of phenotypes must also be
considered, although our study involves highly correlated
traits. As a conservative measure, we may consider a
Bonferroni correction based on three major groups of traits
in our twin/family study: blood pressure (SBP and DBP), uric
acid excretion (urine uric acid: creatinine ratio, FeUA, and
plasma uric acid), and renal function (eGFR and pCr). The
conservative target P-value for significance would then be
0.017 (¼ 0.05/3) in the twin/family study. Thus, pCr and
FeUA would no longer reach statistical significance. However,
we opted to test for replication of the findings in a second
population. In the Kaiser study, two major groups of traits
were studied, BP and renal function. The conservative target
P-value for significance would then be 0.025 (¼ 0.05/2), with
both eGFR and pCr maintaining their significance.
Estimation of renal function. We found that eGFR by
MDRD is highly heritable in twin pairs (77.6±3.4%,
P¼ 7.67E-26). The MDRD equation is most accurate
in subjects with GFRo60 ml/min per 1.73 m2, tending to
underestimate GFR in healthy individuals.46 Standardized
pCr calibrations either to the MDRD reference laboratory or
to the Cleveland Clinic Research Laboratory measurements
have improved accuracy in healthy individuals.47 Our pCr
levels were evaluated with customary quality control external
standards in calibrated automated analyzers, by the Kinetic
Jaffe Reaction, with traceable isotope dilution-mass
spectrometry.48 In limiting the study to subjects with pCro
1.2 mg/dl, within the normal laboratory range, small under-
estimations of GFR likely had minimal effect on associations
that we assessed.
Pleiotropy. Our study illustrates that a single SNP,
particularly in a highly expressed gene in the kidney such
as DRD1, may have several consequences and affect multiple
traits.1 Dopamine has multiple renal actions, including
interactions with other vasoactive substances and their
receptors. It is unclear whether the pleiotropic effects of
G-94A observed here result from actions in parallel or in
series. For example, if DRD1 G-94A alters glomerular
hydrostatic pressure, this may result in simultaneous changes
in eGFR and albuminuria, while the effect on FeUA is more
likely because of receptors in a different region, such as the
renal tubular epithelia.
Functional studies. In addition to our genomic studies, we
assessed the functional consequence of the 50-UTR genetic
polymorphisms in a heterologous system. This is the first
report regarding the role of DRD1 genetic variants on the
expression of cell surface DRD1 receptors. On the basis of
preliminary studies (data not shown), we found that the
heterologous system used in these studies to assess receptor
density is not sensitive enough to display downstream
signaling effects (e.g., cAMP response) of a two- to three-
fold increase in receptor number, although such differences
may be sufficient to affect signaling in vivo. Defining the
precise molecular mechanisms by which cell surface receptor
density is altered by the polymorphism will require future
efforts; such mechanisms may include transcriptional and/or
post-transcriptional (including post-translational) events
that may be altered by the polymorphisms. One potential
mechanism is through a ‘leader cistron,’ by which the
expression of another G-protein-coupled receptor, the b-2
adrenergic receptor, is regulated.42 According to this
mechanism, the 50 leader region of the DRD1 receptor
messenger RNAs containing the -94 polymorphism may act
as a short ORF preceding the receptor cistron and encoding a
small peptide that inhibits receptor translation. Genetic
alteration in this ORF may alter the expression of the
downstream receptor gene. We also acknowledge that
differential receptor expression (especially as determined in
a heterologous system) may not necessarily translate
into differential function on either a cellular or whole
animal level.
Conclusions and perspectives
The DRD1 50-UTR G-94A polymorphism is reproducibly
associated with the highly heritable trait of eGFR in subjects
with predominantly normal or pre-hypertensive blood
pressure. The association with -94A may be a result of
decreased glomerular capillary hydrostatic pressure, as a
consequence of increased receptor expression, but the precise
location in the kidney (tubules, arterioles, podocytes, or
mesangial cells) of the receptors that account for the effect,
and how changes in receptor expression translate into altered
GFR, will require further investigation. As the -94A allele is
relatively common (B15% in our populations), this variant
might be useful in prognostic profiling of subjects with
progressive renal disease.
MATERIALS AND METHODS
Systematic polymorphism discovery at DRD1
Genomic DNA was isolated from blood leukocytes, as has been
previously described49 using PureGene DNA Extraction Kit (Gentra
Systems, Minneapolis, MN, USA). An anonymized sample of 27
unrelated white subjects was used for polymorphism discovery.
PCR and sequencing reactions. PCRs were carried out in MJ
Research Dyad Thermal Cyclers (Waltham, MA, USA). Two sets of
oligonucleotide primers were designed to generate overlapping
fragments of the DRD1 sequence. PCRs of 25 ml were carried out
using 25 ng DNA (or H2O for negative controls), 25 mM MgCl2,
10 mM dNTPs, 20 mM primers, and 0.5 U per reaction of AmpliTaq
Gold DNA Polymerase (Applied Biosystems, Foster City, CA, USA).
The reaction was cycled 40 times with a denaturation step of 95 1C
for 30 s, an annealing step of 65.8 1C for 1 min, an elongation step of
72 1C for 1 min, and a final elongation step of 72 1C for 8 min. PCR
product of 10 ml was used to verify amplification (or the absence of
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amplified product in negative controls) on a 1% agarose gel using
electrophoresis. PCR product of 15 ml was purified with Exonuclease
I (3 U per reaction) and Shrimp Alkaline Phosphatase (0.8 U per
reaction) by incubation at 37 1C for 30 min, then 85 1C for 15 min.
Sequencing reaction was performed according to Applied Biosys-
tems Big Dye Terminator v3.1 Cycle Sequencing Kit Protocol (2002)
and product was purified using Sephadex G-50 DNA Grade beads
(Sigma Scientific, St Louis, MO, USA). Hi-Di Formamide of 10 ml
was added to the sequencing reaction. Sequencing was carried out
on an ABI-3100 capillary device (Applied Biosystems).
Twin/family study
The twin/family UCSD study has previously been described.9 A
total of 428 white (by self-identification) subjects from 195
families, including 168 twin pairs and their siblings met criteria
for this study with a baseline pCr level o1.2 mg/dl. Overall, 78%
were female and 8.9% reported that they had been diagnosed
with hypertension or were on medications. Brachial cuff BPs
(mm Hg) were measured in seated subjects in triplicate using a
DynaPulse oscillometric device (PulseMetric, San Diego, CA, USA)
as previously described and validated.50 Using these triplicate
measurements, we classified 24.3% in the hypertensive range
(SBPX140mm Hg or DBP X90 mm Hg) and 49.8% in the
pre-hypertensive range (120pSBPo140mm Hg or 80pDBP
o90mm Hg). Normotension was defined as SBPo120mm Hg and
DBPo80mm Hg. Plasma and urine samples were obtained for
biologic phenotyping. Urine and pCr values were measured by
autoanalyzer (Beckman-Coulter, Brea, CA, USA) using the Kinetic
Jaffe Reaction with traceable isotope dilution-mass spectrometry.48
Urine uric acid was determined by colorimetric autoanalyzer and
normalized to urine creatinine from the same sample, whereas FeUA
was calculated by the equation FeUA¼ (UUric acid*PCreatinine)/(PUric
acid*UCreatinine). GFR was estimated by the MDRD equation, using
pCr, age, sex, and ethnicity of each subject.46
Subjects were volunteers from Southern California, and each
gave informed, written consent; the protocol was approved by the
UCSD San Diego Human Research Protection Program.
Replication study: Kaiser normal BP group
A replication study was performed on subjects sampled from 53,078
individuals (27,475 women and 25,538 men) whose medical
information was obtained through routine, yearly health appraisal
visits to the Kaiser Permanente Medical Group, a subscription-
based, primary care, health maintenance organization located in San
Diego (CA, USA), which has previously been described.51 We
studied 677 white subjects without a history of hypertension or
history of taking anti-hypertensive medications, sampled from the
lower quantiles of DBP, because twin and family studies have shown
that DBP is substantially heritable.52,53 The mean age of the study
group was 56.8 years, with 57% females. BP was measured in seated
subjects using aneroid sphygmomanometry. If DBP was elevated,
repeat measurement was obtained. sCr was determined in the
Kaiser-Permanente laboratory by spectrophotometric autoanalyzer.
eGFR by MDRD was determined with sCr, age, sex, and ethnicity of
each subject.
Genotyping for association studies
The two SNPs determined by the systematic polymorphism
discovery at the 50-UTR of the DRD1 locus (G-94A rs5326 and
A-48G rs4532) were scored by the Sequenom (San Diego, CA, USA)
MassARRAY matrix-assisted laser desorption ionization time-
of-flight (MALDI-TOF) mass spectrometry system.54 HWE, by w2,
was not maintained for either DRD1 polymorphism in the twin/
family study even after using only one member of each family with
Po0.05 (Table 1). Thus, to confirm genotyping quality in that
study, 48 subjects were selected and re-sequenced across the DRD1
locus (ABI-3100 capillary sequencer; Applied Biosystems) to
evaluate the concordance with a reference standard. This yielded
100 and 97.9% concordance between the ABI-3100 sequencer and
the MALDI-TOF system at the G-94A and A-48G loci, respectively.
HWE was maintained in the Kaiser study.
Statistics
For the twin/family study, descriptive and inferential statistics were
computed with generalized estimating equations (GEE), PROC
GENMOD, in Statistical Analysis System (SAS, Cary, NC, USA),
which consider intra-family correlations by forming an exchange-
able correlation matrix.55 Trait heritability (h2), or the fraction of
trait variance (VP) accounted for by additive genetic variance (VG),
that is, h2¼VG/VP, was estimated from twin (monozygotic versus
dizygotic) data by SOLAR (Sequential Oligogenic Linkage Routines;
http://www.sfbr.org/solar).56 Heritability results are from a subset
(n¼ 374) and have partially been reported previously.9 Univariate
analysis of variance (ANOVA) was carried out using PROC GLM in
SAS for the Kaiser replication study. A combined study with the
twin/family and Kaiser groups was performed with GEEs. In the
instance that inspection of the data suggested a recessive model for
the effect of the minor allele on a trait, statistics were performed for
the major allele homozygotes and the heterozygotes combined.
When data were found to be non-normally distributed, such as with
the measures of urinary uric acid excretion, normalization was
performed by square-root transformation, with presentation of
geometric means.
To adjust for the possibility of multiple comparisons when
testing the effect of two DRD1 SNPs on renal function and
neurohormonal traits, we used the method of SNP Spectral
Decomposition (SNPSpD) proposed by Nyholt44 and implemented
at http://genepi.qimr.edu.au/general/daleN/SNPSpD to yield an
‘effective’ number of markers within a block of LD. For this
purpose, we used SNP data from one member of each family.
This method takes into account intermarker correlations in
calculating a new experiment-wide threshold to keep the type I
error rate at p0.05 for a single phenotype. In this study, statistical
significance was maintained at Po0.05 given that the two
polymorphisms (position -94 and -48) are in substantial linkage
disequilibrium with D0 ¼ 0.81 (n¼ 195 considering only one
member per family), as determined by Haploview57 (http://
www.broad.mit.edu/mpg/haploview/).
Permutation testing was performed using SAS for significant
associations with the DRD1 polymorphisms, which adjusted for the
two genetic models tested. For the twin/family study, the
permutation was performed, accounting for LD between the two
SNPs. The polymorphisms were permuted and analyzed 1000 times,
and the observed test statistic was then ranked to determine
significance using GEE for the twin/family study and ANOVA for
the Kaiser normal BP study.
Statistical power was determined using the online instrument
G*Power 3 (http://www.psycho.uni-duesseldorf.de/abteilungen/aap/
gpower3/literature).58 More than 92% power to detect an effect size
of 0.18 would be achieved with a sample size of 425. For three
groups, the sample size of 428 in the twin/family study required an
effect size (difference in means between two groups over the
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common standard deviation) of 0.19 to reach a¼ 0.05 and b¼ 0.8,
whereas the sample size of 677 in the Kaiser study could detect an
effect size of 0.12. When a recessive model is tested, the sample size
in the twin/family study could detect an effect size of 0.14, whereas
the Kaiser study could detect an effect size of 0.11.
Population stratification
To address potential population stratification in these cohorts of
subjects with self-identified European ancestry, we assessed genetic
heterogeneity of both the twin/family and Kaiser cohorts based on
additional genotyping data available from selected biallelic markers
distributed across the autosomes (19 chromosomes), which were
scored by the Sequenom MassARRAY MALDI-TOF mass spectro-
metry system.54 We carried out a multidimensional scaling analysis
using PLINK 1.6, (http://pngu.mgh.harvard.edu/purcell/plink)59
including 155 markers for the twin/family study and 174 markers
for the Kaiser normal BP study, with overall genotyping rates of 94.5
and 92.1%, respectively. The analysis excluded subjects with o80%
genotypes carried out and SNPs that were out of HWE. For each
cohort, we calculated an IBS allele sharing distance matrix bet-
ween all subjects and extracted the first three multidimensional
scaling components to account for contributions from other major
ancestral backgrounds. To control for potential confounding
because of population stratification, we then used these components
as covariates in the association analyses. Compared with a non-
corrected analysis, the genomic inflation factor (based on the
median w2) was reduced from 1.405 to o1.001, thus showing
adequate power to correct for population stratification.
DRD1 mutant and WT receptors: expression and binding
Plasmid constructs. A human DRD1 was generated by
PCR using human genomic DNA as template with sense primer
50-GATTGACTTGGATTGCCACTC-30 and antisense primer
50-TCTAGCTTTTGGGATGAGCATG-30, resulting in a DRD1 clone
containing the ORF, a 50-UTR of 187 nucleotides upstream of the
start codon, and 30-UTR of 45 nucleotides downstream from the
stop codon. The resultant fragment was cloned into pGEM-T Easy
(Promega, Madison, WI, USA) and sequenced to verify the insert.
NotI fragments were subcloned from these plasmids into pcDNA3.1/
Hygro(þ ) (Invitrogen, Carlsbad, CA, USA) to construct DRD1
expression plasmids, WT (WT receptor sequence), -94A and -48G,
under the control of the CMV promoter.
Cell culture and transient transfection. African green monkey
kidney SV40-T-antigen-transformed COS-7 cells were obtained
from ATCC (Manassas, VA, USA). COS-7 cells were cultured in
Dulbecco’s modified Eagle’s medium (Cellgro, Mediatech, VA,
USA), supplemented with 10% fetal bovine serum (Omega
Scientific, Tarzana, CA, USA) at 37 1C in a humidified atmosphere
containing 5% CO2. Transient transfections were carried out in a
100-mm dish using Lipofectamine Plus reagent (GibcoBRL,
Invitrogen, Carlsbad, CA, USA) with 4 mg of each construct DNA,
and 0.1 mg of pGL3-Promoter vector (Promega), a transfection
efficiency control plasmid in which luciferase expression is driven by
the SV40 early promoter.
Binding assay. DRD1 expression was quantitated by binding of
the radiolabeled DRD1-selective antagonist [3H]SCH23390 (NEN,
Boston, MA, USA). Transfected cells were collected by scraping with
a rubber policeman into ice-cold buffer A: 50 mM Tris-HCl pH 7.4,
1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, 4 mM MgCl2, 120 mM NaCl,
with protease inhibitor cocktail (Sigma, St Louis, MO, USA). Cells
were lysed using a Dounce homogenizer and the homogenate
centrifuged at 300 g for 10 min at 4 1C. The supernatant was
centrifuged at 40,000 g for 20 min at 4 1C, and the pellet resuspended
in buffer A. These membrane fractions were stable at least 3 months
after aliquoting and storage at 701C. For the binding assays,
2 mg of membranes were incubated in triplicate with increasing
concentration of the unlabeled ligand (1 mM–1 pM of SCH23390;
Sigma) and 0.65 nM [3H]SCH23390 (75.5 Ci/mmol) in 0.2 ml buffer
A for 2 h at 25 1C. The binding was terminated by vacuum filtration
through Whatman (Maidstone, Kent, UK) GF/C filters. The filters
were rapidly washed twice with 10 ml of 50 mM Tris-HCl (pH 7.4),
transferred to scintillation vials with 10 ml EcoLume liquid
scintillation cocktail (ICN, Biomedicals, Irvine, CA, USA), and
quantitated in a liquid scintillation counter (Beckman).
Data analyses for binding assays and curve fitting (for Bmax and
Kd) were carried out by non-linear regression using Prism software
(GraphPad, San Diego, CA, USA). Data shown for competitive
binding assays represent triplicate measurements.
mRNA structure: bioinformatics
SNP information and interspecies homology information were
extracted from http://genome.ucsc.edu. Interspecies sequence align-
ments were performed by Clustal-W (http://www.ebi.ac.uk/Tools/es/
cgi-bin/clustalw2). RNA motif predictions were accomplished by
RegRNA (http://regrna.mbc.nctu.edu.tw/index.php). RNA second-
ary structure predictions and folding energy calculations
were performed by GeneBee (http://www.genebee.msu.su/services/
rna2_reduced.html).
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